* 中国石药集团1093.HK周三早盘涨幅扩大至3.3%，创2024年10月29日以来新高。
* 该公司此前公告称，开发的普卢格列汀二甲双胍缓释片已获中国国家药品监督管理局批准，可在中国开展临床试验，获批的临床适应症为配合饮食和运动治疗，用于二甲双胍单药治疗控制不佳或正在接受普卢格列汀与二甲双胍联合治疗的成人2型糖尿病患者。
* 石药集团今年迄今劲涨29.3%，同期恒生指数.HSI上扬9.7%。
* 恒生综合行业指数 - 医疗保健业.HSCIH盘中一度升3.5%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 田镧沁)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.